Evidence map›Paper›PMID 32630020›Full record

ArticleMolecules (Basel, Switzerland)2020

Nicotinic Antagonist UFR2709 Inhibits Nicotine Reward and Decreases Anxiety in Zebrafish.

Franco Viscarra, Juan González-Gutierrez, Erica Esparza, Carla Figueroa, Pablo Paillali, Martin Hödar-Salazar, Camilo Cespedes, Gabriel Quiroz, Ramón Sotomayor-Zárate, Miguel Reyes-Parada and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Franco ViscarraLaboratorio de Síntesis Orgánica y Farmacología Molecular, Departamento de Ciencias Químicas y Recursos Naturales, Facultad de Ingeniería y Ciencias, Universidad de la Frontera, Temuco 4811230, Chile.
Juan González-GutierrezPrograma de Doctorado en Química, Facultad de Ciencias, Universidad de Chile, Santiago 7800003, Chile.
Erica EsparzaLaboratorio de Síntesis Orgánica y Farmacología Molecular, Departamento de Ciencias Químicas y Recursos Naturales, Facultad de Ingeniería y Ciencias, Universidad de la Frontera, Temuco 4811230, Chile.
Carla FigueroaLaboratorio de Síntesis Orgánica y Farmacología Molecular, Departamento de Ciencias Químicas y Recursos Naturales, Facultad de Ingeniería y Ciencias, Universidad de la Frontera, Temuco 4811230, Chile.
Pablo PaillaliLaboratorio de Síntesis Orgánica y Farmacología Molecular, Departamento de Ciencias Químicas y Recursos Naturales, Facultad de Ingeniería y Ciencias, Universidad de la Frontera, Temuco 4811230, Chile.
Martin Hödar-SalazarLaboratorio de Síntesis Orgánica y Farmacología Molecular, Departamento de Ciencias Químicas y Recursos Naturales, Facultad de Ingeniería y Ciencias, Universidad de la Frontera, Temuco 4811230, Chile.
Camilo CespedesLaboratorio de Síntesis Orgánica y Farmacología Molecular, Departamento de Ciencias Químicas y Recursos Naturales, Facultad de Ingeniería y Ciencias, Universidad de la Frontera, Temuco 4811230, Chile.
Gabriel QuirozPrograma de Doctorado en Farmacología, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago 8380494, Chile.
Ramón Sotomayor-ZárateLaboratorio de Neuroquímica y Neurofarmacología, Centro de Neurobiología y Fisiopatología Integrativa (CENFI), Instituto de Fisiología, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2360102, Chile.
Miguel Reyes-ParadaCentro de Investigación Biomédica y Aplicada (CIBAP), Escuela de Medicina, Facultad de Ciencias Médicas, Universidad de Santiago de Chile, Santiago 9170022, Chile.ORCID 0000-0002-2376-990X
Isabel BermúdezDepartment of Biological & Medical Sciences, Faculty of Health & Life Sciences, Oxford Brookes University, Oxford OX3 0BP, UK.
Patricio Iturriaga-VásquezLaboratorio de Síntesis Orgánica y Farmacología Molecular, Departamento de Ciencias Químicas y Recursos Naturales, Facultad de Ingeniería y Ciencias, Universidad de la Frontera, Temuco 4811230, Chile.ORCID 0000-0003-0553-1014
Universidad de La Frontera · CLUniversity of Chile · CLOxford Brookes University · GBUniversidad de Santiago de Chile · CLUniversity of Valparaíso · CL

Funding

National Agency for Research and Development 115-0615 to P.I.-V., 117-0662 to M.R-P. and 120-0474 to R.S.-Z
6 · The paper itself

Abstract

Zebrafish is becoming a popular animal model in neuropharmacology and drug discovery, mainly due to its ease of handling and low costs involved in maintenance and experimental work. This animal displays a series of complex behaviours that makes it useful for assessing the effects of psychoactive drugs. Here, adult zebrafish were used for assessment of the anxiolytic and anti-addictive properties of UFR2709, a nicotinic receptor (nAChR) antagonist, using two behavioural paradigms to test for addiction, the novel tank diving test to assess anxiety and the conditioned place preference (CPP). Furthermore, the expression of nAChR subunits α4 and α7 was measured in the zebrafish brain. The results show that UFR2709 exhibits an anxiolytic effect on zebrafish and blocks the effect evoked by nicotine on CPP. Moreover, UFR2709 significantly decreased the expression of α4 nicotinic receptor subunit. This indicates that UFR2709 might be a useful drug for the treatment of nicotine addiction.

Indexed as

RewardAnimalsAnti-Anxiety AgentsAnxietyBehavior, AnimalBenzoatesDisease Models, AnimalNicotineNicotinic AntagonistsPyrrolidinesReceptors, NicotinicSwimmingZebrafishAnti-Anxiety AgentsBenzoatesNicotineNicotinic AntagonistsPyrrolidinesReceptors, NicotinicUFR2709anxietyconditioned place preference (CPP)nicotinic receptornovel tank test (NTT)rewardzebrafish

Identifiers

PMID32630020
PMCPMC7412259
OpenAlexW3039618877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.